Guided by the results from our Columbia cohort, we derived volumetric measurements in the ADNI cohort, in participants who did not meet the current clinical and CSF biomarker criteria for AD, using a combination of CSF tau and Aβ1–42, with the most reliable CSF indicator of disease [24–26]. This evidence concerns the gene MAPT and Alzheimer disease.